Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BAROSTIM THERAPY™ In Resistant Hypertension

NCT: NCT02880631 · RECRUITING

NCT IDNCT02880631
StatusRECRUITING
Start Date2016-12-13
Completion2027-07
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

Frequently Asked Questions

What is BAROSTIM THERAPY™ In Resistant Hypertension?

BAROSTIM THERAPY™ In Resistant Hypertension is a clinical trial registered under NCT02880631. Current status: RECRUITING.

What is the status of NCT02880631?

The current status of NCT02880631 (BAROSTIM THERAPY™ In Resistant Hypertension) is: RECRUITING.

When did BAROSTIM THERAPY™ In Resistant Hypertension start?

BAROSTIM THERAPY™ In Resistant Hypertension started on 2016-12-13.

Related Devices

PMA P180050Stimulator, carotid sinus nerveCvrx, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑